Skip to main content
. Author manuscript; available in PMC: 2017 Mar 27.
Published in final edited form as: Nat Rev Immunol. 2016 May 27;16(6):378–391. doi: 10.1038/nri.2016.49

Table 1.

Drugs in current clinical trials that specifically target neutrophil migration signals

Drug name Target Disease or model Stage Reference
SCH 527123 CXCR2 Severe asthma, allergen-induced asthma, COPD, psoriasis and colon cancer Phase I–II 185
Reparixin CXCR1 and CXCR2 Ischemia-reperfusion injury; lung, pancreatic islet and kidney transplantation, and breast cancer Phase II–III 186
DF 2156A CXCR1 and CXCR2 Active bullous pemphigoid Phase II -
AZD-8309 CXCR1 and CXCR2 LPS-induced airway inflammation Phase I 187
SB-656933 CXCR2 Ulcerative colitis, cystic fibrosis and ozone airway inflammation Phase I–II 132
GSK1325756 CXCR2 Influenza virus infection and healthy volunteers Phase II 188
AZD5069 CXCR2 Healthy volunteers and LPS-induced airway inflammation Phase I 189
190
QBM076 Not known COPD Phase II -

COPD, chronic obstructive pulmonary disease; CXCR, CXC-chemokine receptor; LPS, lipopolysaccharide. More details at clinicaltrials.gov.